Medscape

Etravirine: A Novel Nonnucleoside Reverse Transcriptase Inhibitor for Managing Human Immunodeficiency Virus Infection

Purpose: The pharmacology, efficacy, and safety of etravirine and its clinical utility with respect to the available alternative human immunodeficiency virus (HIV) treatment options are reviewed.
MSN on MSN

Gilead, Merck report positive phase III HIV study data, end NSCLC study

Gilead Sciences, Inc. GILD and partner Merck MRK announced positive data from two late-stage studies, ISLEND-1 and ISLEND-2, ...
EurekAlert!

Diversity of reverse-transcriptase-containing viruses through global metagenomics

Viral reverse transcriptase (RT) plays a critical role in replication (e.g., retroviruses, that reverse transcribe RNA templates into complementary DNA) and genome mutations (e.g., ...
Infectious Disease Advisor

Phase 3 Trials Support Oral, Once-Weekly Islatravir/Lenacapavir for HIV

Gilead and Merck announce positive phase 3 results for once-weekly oral islatravir/lenacapavir, demonstrating noninferiority in virologically suppressed HIV.
Pharmabiz

Gilead & Merck announce positive topline results from two phase 3 studies evaluating islatravir/lenacapavir, an oral once-weekly HIV treatment

Gilead & Merck announce positive topline results from two phase 3 studies evaluating islatravir/lenacapavir, an oral once-weekly HIV treatment: Foster City, California Wednesday, ...
Labroots

De novo gene synthesis by an antiviral reverse transcriptase

Bacteria defend themselves from viral infection using diverse immune systems, many of which sense and target foreign nucleic acids. Defense-associated reverse transcriptase (DRT) systems provide an ...